Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Abbott (ABT) tops consensus expectations despite decline in Covid-19 testing related sales
January 25, 2023 9:46 AM ESTAbbott (NYSE: ABT) shares fell Wednesday despite topping consensus expectations for profit and revenue.
The medical device firm reported adjusted fourth-quarter earnings of $1.03 per share, $0.11 better than the analyst estimate of $0.92.
Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.62 billion.... More
Abbott (ABT) Tops Q4 EPS by 11c, Revenues Beat
January 25, 2023 7:31 AM ESTAbbott (NYSE: ABT) reported Q4 EPS of $1.03, $0.11 better than the analyst estimate of $0.92. Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.62 billion.
GUIDANCE:
Abbott sees FY2023 EPS of $4.30-$4.50, versus the consensus of $4.40.
For earnings history and earnings-related data on Abbott (ABT) click here.
... More